Evaluation of PSMA PET/CT imaging using a 68 Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging

Nuclear Medicine Communications

Volumn 36, Issue 6, 2015, Pages 582-587

  Kabasakal, Levent ^a   Demirci, Emre ^c   Ocak, Meltem ^b   Akyel, Reşit ^a   Nematyazar, Jamal ^a   Aygun, Aslan ^a   Halac, Metin ^a   Talat, Zubeyir ^a   Araman, Ahmet ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Pharmacy Faculty   (Turkey)

^c SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

68 Ga HBED CC; bone metastases; carboxypeptidase; glutamate; lymph node metastases; PET CT; prostate; prostate cancer; prostate specific membrane antigen

Indexed keywords

HBED CC GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN INHIBITOR; TRACER; UNCLASSIFIED DRUG; EDETIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LIGAND; MEMBRANE ANTIGEN; N,N'-BIS(2-HYDROXY-5-(ETHYLENE-BETA-CARBOXY)BENZYL)ETHYLENEDIAMINE N,N'-DIACETIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PET-CT SCANNER; PROSTATE CANCER; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; PELVIS; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; EDETIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PELVIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84929162229     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000290     Document Type: Article

References (20)

1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30:195-200.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65:124-137.
3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467-479.
4. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 2012; 61:1132-1138.
5. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottagy F, Deroose CM, et al. Prospective evaluation of C-11-choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk lymph node metastases. Eur Urol 2011; 60:125-130.
6. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, et al. The role of radical prostatectomy and lymph node dissection in lymph node positive prostate cancer: a systematic review of the literature. Eur Urol 2013; 22:S0302-S2838.
7. 11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014; 41:694-701.
8. Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, et al. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Int J Radiat Oncol Biol Phys 2013; 87:960-967.
9. Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013; 23:1745-1752.
10. Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, et al. C-11-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014; 41:878-886.
11. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1:18-28.
12. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38:696-701.
13. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326-334.
14. Silver DA, Pelicer I, Fair RF, Heston WDW, Cordon-Cardo C. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81-85.
15. Eder M, Schafer M, Baeder-Wüst U, Hull WE, Wangler C, Mier W, et al. Ga-68-complex lipophilicity and the targeting property of urea-based PSMA inhibitor for PET imaging. Biconjug Chem 2012; 23:688-697.
16. Eder M, Schafer M, Bauder-Würst U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targetting both PSMA and GRPR for improved imaging and therapy of prostate cancer. Prostate 2014; 74:659-668.
17. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschick BA, et al. PET imaging with a (Ga-68)gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40:486-495.
18. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41:11-20.
19. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using Ga-68-labelled PSMA ligand fort he diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014; 41:887-897.
20. Loriot Y, Massard C, Fizazi K. Recent developments in treatments targetting castration-resistant prostate cancer bone metastases. Ann Oncol 2012; 23:1085-1094.